Exemestane: one option of several
111 studies: a test or a strategy chooses among drugs. Page 1 of 2. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerNot yet recruitingNCT07935317Phase 2Report a problem
- Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast CancerRecruitingNCT07810088Phase 2Report a problem
- Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerRecruitingNCT07796880Phase 2Report a problem
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingNCT07782840Phase 2Report a problem
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingNCT07729046Phase 2Report a problem
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab FailureRecruitingNCT07708194Phase 1/2Report a problem
- Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNot yet recruitingNCT07687225Not applicableReport a problem
- Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNot yet recruitingNCT07618923Phase 2Report a problem
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2Report a problem
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingNCT07581834Phase 2Report a problem
- Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant ChemotherapyRecruitingNCT07400523Phase 3Report a problem
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low TrialRecruitingNCT07391774Phase 3Report a problem
- An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast CancerNot yet recruitingNCT07300215Phase 2Report a problem
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2Report a problem
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Phase 3Report a problem
- Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNot yet recruitingNCT07101159Phase 2Report a problem
- Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast CancerNot yet recruitingNCT07061717Phase 3Report a problem
- CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)RecruitingNCT07019363Phase 3Report a problem
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.RecruitingNCT06590857Phase 1/2Report a problem
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3Report a problem
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingNCT06369285Phase 2Report a problem
- A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBCRecruitingNCT06235931Not applicableReport a problem
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRecruitingNCT06218303Phase 1Report a problem
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingNCT06179303Phase 2Report a problem
- Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast CancerRecruitingNCT06149130Phase 2Report a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2Report a problem
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsRecruitingNCT06044623Phase 3Report a problem
- Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast CancerRecruitingNCT05983107Phase 2Report a problem
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingNCT05949541Phase 2Report a problem
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingNCT05894239Phase 3Report a problem
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingNCT05891093Phase 3Report a problem
- A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line ChemotherapyRecruitingNCT05890287Not applicableReport a problem
- Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.RecruitingNCT05872347Phase 2Report a problem
- Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast CancerRecruitingNCT05861271Phase 2Report a problem
- NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast CancerRecruitingNCT05837455Phase 2Report a problem
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2Report a problem
- Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationNCT05645536Phase 3Report a problem
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2Report a problem
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingNCT05467891Phase 2Report a problem
- The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral CrisisNot yet recruitingNCT05431504Phase 2Report a problem
- Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect ManagementRecruitingNCT05362760Phase 4Report a problem
- De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)RecruitingNCT04852887Phase 3Report a problem
- Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast CancerRecruitingNCT03750396Phase 2Report a problem
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast CancerActive, not recruitingNCT06001762Phase 2Results postedReport a problem
- Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerTerminatedNCT03874325Phase 2Results postedReport a problem
- Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisCompletedNCT03691493Phase 2Results postedReport a problem
- MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.CompletedNCT03321981Phase 2Results postedReport a problem
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerCompletedNCT03280563Phase 1/2Results postedReport a problem
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast CancerCompletedNCT03179904Phase 2Results postedReport a problem
- Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast CancerCompletedNCT03078751Phase 2Results postedReport a problem
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast CancerActive, not recruitingNCT02947685Phase 3Results postedReport a problem
- Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT02648477Phase 2Results postedReport a problem
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast CancerCompletedNCT02291913Phase 2Results postedReport a problem
- Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk ScoreTerminatedNCT02236572Phase 2Results postedReport a problem
- Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02213042Phase 2Results postedReport a problem
- Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast CancerCompletedNCT02040857Phase 2Results postedReport a problem
- Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast CancerTerminatedNCT01897441Not applicableResults postedReport a problem
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone TherapyCompletedNCT01720602Not applicableResults postedReport a problem
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingNCT01674140Phase 3Results postedReport a problem
- Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast CancerTerminatedNCT01484041Phase 1/2Results postedReport a problem
- Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast CancerCompletedNCT01446159Phase 2Results postedReport a problem
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerActive, not recruitingNCT01272037Phase 3Results postedReport a problem
- Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast CancerTerminatedNCT01220128Phase 2Results postedReport a problem
- A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerCompletedNCT01160211Phase 3Results postedReport a problem
- Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor TherapyCompletedNCT01153672Not applicableResults postedReport a problem
- Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is ProgressingCompletedNCT00828854Phase 2Results postedReport a problem
- A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast CancerCompletedNCT00728949Phase 2Results postedReport a problem
- QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00626106Phase 2Results postedReport a problem
- Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast CancerTerminatedNCT00573755Phase 2Results postedReport a problem
- Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)Active, not recruitingNCT00310180Phase 3Results postedReport a problem
- Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.CompletedNCT00240071Phase 2Results postedReport a problem
- Premenopausal Endocrine Responsive Chemotherapy TrialTerminatedNCT00066807Phase 3Results postedReport a problem
- Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard TherapyActive, not recruitingNCT06957379Phase 2Report a problem
- Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerActive, not recruitingNCT06447623Phase 3Report a problem
- First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerCompletedNCT06375707Phase 2Report a problem
- Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABCCompletedNCT05969184Phase 2Report a problem
- Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingNCT05827081Phase 3Report a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingNCT05826964Phase 2Report a problem
- Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast CancerActive, not recruitingNCT05463601Phase 2Report a problem
- Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.Status unknownNCT05411380Phase 2Report a problem
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingNCT05307705Phase 1Report a problem
- Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerActive, not recruitingNCT04906395Phase 3Report a problem
- PreOperative Endocrine Therapy for Individualised Care With AbemaciclibActive, not recruitingNCT04584853Phase 3Report a problem
- Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast CancerTerminatedNCT04460430Phase 2Report a problem
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC PatientsCompletedNCT04300790Phase 2Report a problem
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingNCT04188548Phase 1Report a problem
- Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast CancerStatus unknownNCT04088110Phase 2Report a problem
- Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWithdrawnNCT04088032Early Phase 1Report a problem
- Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBCStatus unknownNCT03910712Phase 2Report a problem
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive, not recruitingNCT03820830Phase 3Report a problem
- Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerCompletedNCT03555877Phase 2Report a problem
- T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast CancerCompletedNCT03554044Phase 1Report a problem
- Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyTerminatedNCT03220178Phase 4Report a problem
- Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCCompletedNCT03184090Phase 2Report a problem
- Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWithdrawnNCT03081234Phase 3Report a problem
- Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast CancerStatus unknownNCT02910050Phase 2Report a problem
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2Report a problem
- Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast CancerCompletedNCT02767661Phase 3Report a problem
- NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast CancerStatus unknownNCT02689921Phase 2Report a problem
- Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive TumorsActive, not recruitingNCT02592083Phase 2Report a problem